Literature DB >> 6744718

A comparison of the posterolateral and anterolateral approaches to total hip arthroplasty.

J M Roberts, F H Fu, E J McClain, A B Ferguson.   

Abstract

A comparative statistical analysis was performed weighing the relative merits of two surgical approaches for total hip arthroplasty--the Watson-Jones anterolateral approach and the gluteus maximus splitting posterolateral approach. Intraoperative and clinical records were evaluated for 175 patients undergoing total hip arthroplasty between 1975 and 1979--100 by a posterolateral approach and 75 by an anterolateral approach. Minimum follow-up period was two years. Mean operative times for the posterolateral and anterolateral approaches were 62 minutes and 140 minutes, respectively. The posterolateral group had a mean blood loss of 433 ml, with 35% requiring an average transfusion of 2.5 units. The anterolateral group had a mean blood loss of 767 ml, with 78% requiring an average transfusion of 2.5 units. The average lengths of hospitalization for posterolateral and anterolateral groups were 13 and 15 days, respectively. The time to independent cane ambulation was significantly less in the posterolateral group. The rate of post-operative complications was similar in each group. However, in the posterolateral group there were four dislocations, three loosened femoral components, one deep-wound infection, and one pulmonary embolus, while the anterolateral group suffered one dislocation, no prosthesis loosening, no deep-wound infections, and three pulmonary emboli. Although the posterolateral approach was associated with a lower perioperative morbidity than the anterolateral approach, the latter exhibited fewer dislocations and loosened acetabular components.

Entities:  

Mesh:

Year:  1984        PMID: 6744718

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  16 in total

1.  [The medial approach for total hip replacement].

Authors:  W Thomas; L Lucente; P Benecke; C L Busch; H Grundei
Journal:  Orthopade       Date:  2006-07       Impact factor: 1.087

2.  [Conventional vs minimally invasive total hip arthroplasty. A prospective study of rehabilitation and complications].

Authors:  S B Murphy; M Tannast
Journal:  Orthopade       Date:  2006-07       Impact factor: 1.087

3.  [Not Available].

Authors:  E Engelbrecht; T Gehrke
Journal:  Oper Orthop Traumatol       Date:  1997-12       Impact factor: 1.154

4.  Modified posterior approach to total hip arthroplasty to enhance joint stability.

Authors:  Yong Sik Kim; Soon Yong Kwon; Doo Hoon Sun; Suk Ku Han; William J Maloney
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

5.  Blood loss during primary total hip arthroplasty: use of preoperative measurements to predict the need for transfusion.

Authors:  R W Walker; J R Rosson; J M Bland
Journal:  Ann R Coll Surg Engl       Date:  1997-11       Impact factor: 1.891

6.  [Earlier postoperative mobilization with minimally invasive hip hemiarthroplasty].

Authors:  B Preininger; M Jesacher; E Fabsits; T Winkler
Journal:  Unfallchirurg       Date:  2011-04       Impact factor: 1.000

7.  Dislocation after total hip arthroplasty with 28 and 32-mm femoral head.

Authors:  Einar Amlie; Øystein Høvik; Olav Reikerås
Journal:  J Orthop Traumatol       Date:  2010-05-27

Review 8.  Blood loss in total hip replacement. A retrospective study.

Authors:  P A Flordal; G Neander
Journal:  Arch Orthop Trauma Surg       Date:  1991       Impact factor: 3.067

9.  Which approach for total hip arthroplasty: anterolateral or posterior?

Authors:  Jeya Palan; David J Beard; David W Murray; J G Andrew; John Nolan
Journal:  Clin Orthop Relat Res       Date:  2008-10-22       Impact factor: 4.176

10.  Dislocations after use of dual-mobility cups in cementless primary total hip arthroplasty: prospective multicentre series.

Authors:  Ji-Hyo Hwang; Sang-Min Kim; Kwang-Jun Oh; Yeesuk Kim
Journal:  Int Orthop       Date:  2017-10-07       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.